All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @gwen.in.doubt on TikTok · 94s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @gwen.in.doubt's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Hey, here is the Victosa update that everybody's been asking for I'm nine months in
  2. 0:06I'm
  3. 0:08Feeling great on the medication currently. I'm feeling like crap because I have this chrome flare up
  4. 0:14That's really bad and I am on my period. So I'm bloated and I feel like crap and
  5. 0:22I'm just not feeling it right now. I'm on the 1.8. I have been on the 1.8 since
  6. 0:28March or February
  7. 0:32I've done really well, I've lost 50 pounds probably over 50 pounds
  8. 0:36I was really gonna do the math. I'm down to 165 now
  9. 0:40Which is 10 pounds from my goal weight 155 is kind of my goal like where I feel like I'll be happy at
  10. 0:47I have no side effects. I feel fine. I just take my shot every day and that's it
  11. 0:54I
  12. 0:56I'm gonna show you in a second just like how my body looks
  13. 1:01Even with me being bloated even with me being in a chrome flare up
  14. 1:05I you can visibly see a change in the way that my body looks my clothes fit looser
  15. 1:13My tummy is flatter, you know, you can see the bloke there. I'm not sucking in
  16. 1:18I'm just kind of showing you what I look like and I feel great
  17. 1:21I feel happy with the way that my body is looking
  18. 1:23But anyways, if you have any more questions put them below in the comments and I will try to answer

Victoza for weight loss: what 9 months of GLP-1 data actually shows

gwenindoubt🤠

TikTok creator

69.5K viewsWatch on TikTok

Quick answer

The creator is using liraglutide (Victoza) at 1.8 mg daily for weight management, which is an off-label use. Victoza is FDA-approved for type 2 diabetes; Saxenda (liraglutide 3.0 mg) is the approved formulation for chronic weight management. Her concurrent Crohn's disease is clinically relevant, as GLP-1 receptor agonists have gastrointestinal effects that may interact with inflammatory bowel disease, and any prescriber should factor in that condition when evaluating liraglutide candidacy.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Victoza for weight loss: what 9 months of GLP-1 data actually shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Victoza for weight loss: what 9 months of GLP-1 data actually shows is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Victoza for weight loss: what 9 months of GLP-1 data actually shows" from gwenindoubt🤠. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator is using liraglutide (Victoza) at 1.

The reason this review is not generic is the source wording and the canonical claim label "glp1 9 months on victoza victoza weightloss weightlossprogress fi." In this clip, the useful excerpt is: "Hey, here is the Victosa update that everybody's been asking for I'm nine months in I'm Feeling great on the medication currently." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference (2025), Discontinuing glucagon-like peptide-1 receptor agonists and body habitus (2025), and Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition (2025), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al.
People who land here are usually comparing the GLP-1 social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator is using liraglutide (Victoza) at 1.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator is using liraglutide (Victoza) at 1.8 mg daily for weight management, which is an off-label use. Victoza is FDA-approved for type 2 diabetes; Saxenda (liraglutide 3.0 mg) is the approved formulation for chronic weight management. Her concurrent Crohn's disease is clinically relevant, as GLP-1 receptor agonists have gastrointestinal effects that may interact with inflammatory bowel disease, and any prescriber should factor in that condition when evaluating liraglutide candidacy.
  • Victoza (liraglutide 1.8 mg) is FDA-approved for type 2 diabetes, not weight loss. Saxenda (liraglutide 3.0 mg) is the approved weight-management formulation. Using Victoza for weight loss is off-label.
  • The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, NEJM) found average weight loss of about 8% of body weight at liraglutide 3.0 mg. A 50 lb loss at the lower 1.8 mg dose is an above-average individual outcome.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Victoza (liraglutide 1.8 mg) is FDA-approved for type 2 diabetes, not weight loss. Saxenda (liraglutide 3.0 mg) is the approved weight-management formulation. Using Victoza for weight loss is off-label.
  • The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, NEJM) found average weight loss of about 8% of body weight at liraglutide 3.0 mg. A 50 lb loss at the lower 1.8 mg dose is an above-average individual outcome.
  • Roughly 40% of patients in liraglutide clinical trials reported nausea. Claiming 'no side effects' is a personal experience, not a reliable expectation for other users.
  • A 2021 meta-analysis by Shi et al. in Obesity Reviews confirmed that liraglutide's weight loss effects are dose-dependent, meaning higher doses produce greater results on average. The 1.8 mg dose typically underperforms the 3.0 mg dose for weight management.
  • Patients with Crohn's disease should consult both a gastroenterologist and their prescribing physician before starting a GLP-1 receptor agonist. A 2023 review (Gros et al., Alimentary Pharmacology and Therapeutics) found preliminary evidence of anti-inflammatory effects but noted the data is not yet sufficient for clinical recommendations.
  • GLP-1 receptor agonists require a valid prescription and individualized clinical evaluation. Individual results vary significantly, and social media outcomes should not be used as benchmarks for expected weight loss.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @gwen.in.doubt actually say?

Gwen says she has been on Victoza (liraglutide) for nine months, currently at the 1.8 mg daily dose, and has lost "probably over 50 pounds," bringing her from an implied starting weight down to 165 lbs. She claims "no side effects" and says she just takes her shot daily with no issues. She also mentions an active Crohn's flare and period bloating, which she's careful to separate from the medication's effects. That transparency is worth noting.

She is not making wild promises about the drug. She is documenting her own experience, which is a meaningful distinction. But some of what she implies, especially the zero-side-effect claim and the framing of 50 lbs as a straightforward result of Victoza alone, deserves a closer look.

Does the science back this up?

Partially. Liraglutide at 3.0 mg daily (branded as Saxenda) is the FDA-approved dose for weight management. Victoza is approved for type 2 diabetes at doses up to 1.8 mg. Using Victoza at 1.8 mg for weight loss is off-label, and the clinical weight loss data at that dose is less robust than at 3.0 mg.

The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, NEJM) found that liraglutide 3.0 mg produced an average weight loss of about 8% of body weight over 56 weeks in adults without diabetes. Gwen appears to have lost significantly more than that, which is possible depending on starting weight and adherence but is above the average clinical outcome. A 2021 meta-analysis by Shi et al. in Obesity Reviews confirmed that weight loss with liraglutide is dose-dependent, meaning the 1.8 mg dose typically produces less weight reduction than 3.0 mg. Losing 50+ lbs at 1.8 mg is on the high end of what the literature would predict.

What did they get wrong (or right)?

The "no side effects" claim is where this gets complicated. Gwen says she feels fine and has had no side effects from the medication. That experience is real and valid for her. But it is not representative. In the SCALE trial, roughly 40% of liraglutide users reported nausea, and around 13-17% reported vomiting. Diarrhea and constipation are also common. Saying "I have no side effects" is fine as a personal report. Saying it in a way that implies this is normal or expected for everyone is misleading.

What she got right: she is upfront about her Crohn's disease and period bloating, she does not claim Victoza treats or cures anything, and she is not pushing anyone to take the drug. She just answers questions about her own body. That is genuinely responsible content for TikTok. She also correctly identifies her dose (1.8 mg) rather than conflating Victoza with Ozempic or Wegovy, which is a common error in this space.

What should you actually know?

A few things matter here if you are watching this video and considering liraglutide for weight loss. First, Victoza at 1.8 mg is not FDA-approved for weight management. Saxenda (liraglutide 3.0 mg) is the approved version for that indication. They are the same molecule at different doses prescribed for different purposes. Using Victoza off-label for weight loss is something a prescriber would need to evaluate individually, and insurance coverage may differ significantly.

Second, Gwen's Crohn's disease adds a layer of complexity her video doesn't address. GLP-1 receptor agonists can affect gastrointestinal motility, and their interaction with inflammatory bowel disease is still an active area of research. A 2023 review by Gros et al. in Alimentary Pharmacology and Therapeutics noted that GLP-1 agonists may have anti-inflammatory properties relevant to IBD, but the evidence is preliminary. Anyone with Crohn's considering these medications should have that conversation explicitly with a gastroenterologist, not just a general prescriber.

Third, 50 lbs of weight loss in 9 months is not a guaranteed or even average outcome. Managing expectations matters. The drug works for many people, but the average result is more modest than Gwen's experience.

Bottom line

This video is more responsible than most GLP-1 content on TikTok. Gwen is documenting her own experience without overpromising. The "no side effects" framing is the weakest part of the video because it could create unrealistic expectations. Her results are real but above average, and the off-label nature of using Victoza specifically for weight loss is worth understanding before you ask your doctor for the same prescription.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

gwenindoubt🤠 · TikTok creator

69.5K views on this video

9 months on Victoza #victoza #weightloss #weightlossprogress #fitnessjourney #weightlossmotivation

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about victoza (liraglutide 1.8 mg)?

Victoza (liraglutide 1.8 mg) is FDA-approved for type 2 diabetes, not weight loss. Saxenda (liraglutide 3.0 mg) is the approved weight-management formulation. Using Victoza for weight loss is off-label.

What does the video say about the scale obesity?

The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, NEJM) found average weight loss of about 8% of body weight at liraglutide 3.0 mg. A 50 lb loss at the lower 1.8 mg dose is an above-average individual outcome.

What does the video say about roughly 40% of patients in liraglutide clinical trials reported nausea.?

Roughly 40% of patients in liraglutide clinical trials reported nausea. Claiming 'no side effects' is a personal experience, not a reliable expectation for other users.

What does the video say about a 2021 meta-analysis by shi et al. in obesity reviews?

A 2021 meta-analysis by Shi et al. in Obesity Reviews confirmed that liraglutide's weight loss effects are dose-dependent, meaning higher doses produce greater results on average. The 1.8 mg dose typically underperforms the 3.0 mg dose for weight management.

What does the video say about patients with crohn's disease should consult both a gastroenterologist?

Patients with Crohn's disease should consult both a gastroenterologist and their prescribing physician before starting a GLP-1 receptor agonist. A 2023 review (Gros et al., Alimentary Pharmacology and Therapeutics) found preliminary evidence of anti-inflammatory effects but noted the data is not yet sufficient for clinical recommendations.

What does the video say about glp-1 receptor agonists require a valid prescription?

GLP-1 receptor agonists require a valid prescription and individualized clinical evaluation. Individual results vary significantly, and social media outcomes should not be used as benchmarks for expected weight loss.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by gwenindoubt🤠, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.